Summary of BRCA1
The Function of BRCA1
E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Component of the BRCA1-RBBP8 complex which regulates CHEK1 activation and controls cell cycle G2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination of RBBP8. Acts as a transcriptional activator (PubMed:20160719).
Protein names
Recommended name:
Breast cancer type 1 susceptibility proteinAlternative name(s):
RING finger protein 53RING-type E3 ubiquitin transferase BRCA1
- RS11655505 (BRCA1) ??
- RS16942 (BRCA1) ??
- RS1799950 (BRCA1) ??
- RS1799966 (BRCA1) ??
- RS1799967 (BRCA1) ??
- RS1800709 (BRCA1) ??
- RS1800747 (BRCA1) ??
- RS2227945 (BRCA1) ??
- RS28897672 (BRCA1) ??
- RS28897686 (BRCA1) ??
- RS28897696 (BRCA1) ??
- RS3737559 (BRCA1) ??
- RS41293455 (BRCA1) ??
- RS41293463 (BRCA1) ??
- RS45553935 (BRCA1) ??
- RS4986850 (BRCA1) ??
- RS4986852 (BRCA1) ??
- RS4986854 (BRCA1) ??
- RS55770810 (BRCA1) ??
- RS62625307 (BRCA1) ??
- RS799906 (BRCA1) ??
- RS799917 (BRCA1) ??
- RS8176318 (BRCA1) ??
To see your genotype, you should be logged in and have a file with your genotype uploaded.
Top Gene-Substance Interactions
BRCA1 Interacts with These Diseases
| Disease | Score |
Fixes
Substances That Increase BRCA1
| Substances | Interaction | Organism | Category |
Substances That Decrease BRCA1
| Substances | Interaction | Organism | Category |
Advanced Summary
BRCA1 is a tumor suppressor gene and is responsible for DNA repairs as well as playing a role in transcription and recombination (R).
Mutations in this gene can cause breast or ovarian cancer (R).
breast cancer Researchers have identified more than 1,800 mutations in the BRCA1 gene. Many of these mutations are associated with an increased risk of breast cancer in both men and women, as well as several other types of cancer. These mutations are present in every cell in the body and can be passed from one generation to the next. As a result, they are associated with cancers that cluster in families. However, not everyone who inherits a mutation in the BRCA1 gene will develop cancer. Other genetic, environmental, and lifestyle factors also contribute to a person's cancer risk. Most BRCA1 gene mutations lead to the production of an abnormally short version of the BRCA1 protein or prevent any protein from being made from one copy of the gene. As a result, less of this protein is available to help repair damaged DNA or fix mutations that occur in other genes. As these defects accumulate, they can trigger cells to grow and divide uncontrollably to form a tumor. ovarian cancer Many of the same BRCA1 gene mutations that increase the risk of breast cancer (described above) also increase the risk of ovarian cancer. Families with these mutations are often said to be affected by hereditary breast and ovarian cancer syndrome. Women with BRCA1 gene mutations have a 35 to 60 percent chance of developing ovarian cancer in their lifetimes, as compared with 1.6 percent in the general population. prostate cancer At least five inherited BRCA1 gene mutations have been found to increase the risk of prostate cancer. These mutations likely reduce the BRCA1 protein's ability to repair DNA, allowing potentially damaging mutations to persist in various other genes. The accumulation of damaging mutations can lead to the out-of-control cell growth and division that can cause a tumor to develop. Men who carry a BRCA1 gene mutation that increases the risk of prostate cancer may also be at increased risk for other cancers. other cancers Inherited mutations in the BRCA1 gene also increase the risk of several other types of cancer, including pancreatic cancer and colon cancer. These mutations impair the ability of the BRCA1 protein to help repair damaged DNA. As defects accumulate in DNA, they can trigger cells to grow and divide without order to form a tumor. It is not clear why different individuals with BRCA1 mutations develop cancers in different organs. Environmental factors that affect specific organs may contribute to the development of cancers at particular sites.
The BRCA1 gene provides instructions for making a protein that acts as a tumor suppressor. Tumor suppressor proteins help prevent cells from growing and dividing too rapidly or in an uncontrolled way. The BRCA1 protein is involved in repairing damaged DNA. In the nucleus of many types of normal cells, the BRCA1 protein interacts with several other proteins to mend breaks in DNA. These breaks can be caused by natural and medical radiation or other environmental exposures, and they also occur when chromosomes exchange genetic material in preparation for cell division. By helping to repair DNA, the BRCA1 protein plays a critical role in maintaining the stability of a cell's genetic information. Research suggests that the BRCA1 protein also regulates the activity of other genes and plays an essential role in embryonic development. To carry out these functions, the BRCA1 protein interacts with many other proteins, including other tumor suppressors and proteins that regulate cell division.
Conditions with Increased Gene Activity
| Condition | Change (log2fold) | Comparison | Species | Experimental variables | Experiment name |
|---|
Conditions with Decreased Gene Activity
| Condition | Change (log2fold) | Comparison | Species | Experimental variables | Experiment name |
|---|
Technical
The following transcription factors affect gene expression:
Tissue specificity:
Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.
Gene Pathways:
Enzyme Regulation:
The E3 ubiquitin-protein ligase activity is inhibited by phosphorylation by AURKA. Activity is increased by phosphatase treatment.
Molecular Function:
- Androgen Receptor Binding
- Damaged Dna Binding
- Dna Binding
- Enzyme Binding
- Rna Binding
- Transcription Coactivator Activity
- Transcription Regulatory Region Dna Binding
- Tubulin Binding
- Ubiquitin Protein Ligase Binding
- Ubiquitin-Protein Transferase Activity
- Zinc Ion Binding
- Chromatin Binding
- Ligase Activity
Biological Processes:
- Androgen Receptor Signaling Pathway
- Apoptotic Process
- Cellular Response To Dna Damage Stimulus
- Cellular Response To Indole-3-Methanol
- Cellular Response To Tumor Necrosis Factor
- Centrosome Cycle
- Chordate Embryonic Development
- Chromosome Breakage
- Chromosome Segregation
- Dna Damage Response, Signal Transduction By P53 Class Mediator Resulting In Transcription Of P21 Class Mediator
- Dna Double-Strand Break Processing
- Dna Replication
- Dna Synthesis Involved In Dna Repair
- Dosage Compensation By Inactivation Of X Chromosome
- Double-Strand Break Repair
- Double-Strand Break Repair Via Homologous Recombination
- Double-Strand Break Repair Via Nonhomologous End Joining
- Fatty Acid Biosynthetic Process
- G2 Dna Damage Checkpoint
- Intrinsic Apoptotic Signaling Pathway In Response To Dna Damage
- Negative Regulation Of Centriole Replication
- Negative Regulation Of Extrinsic Apoptotic Signaling Pathway Via Death Domain Receptors
- Negative Regulation Of Fatty Acid Biosynthetic Process
- Negative Regulation Of Histone Acetylation
- Negative Regulation Of Histone H3-K4 Methylation
- Negative Regulation Of Histone H3-K9 Methylation
- Negative Regulation Of Intracellular Estrogen Receptor Signaling Pathway
- Negative Regulation Of Reactive Oxygen Species Metabolic Process
- Negative Regulation Of Transcription, Dna-Templated
- Positive Regulation Of Angiogenesis
- Positive Regulation Of Cell Cycle Arrest
- Positive Regulation Of Dna Repair
- Positive Regulation Of Gene Expression
- Positive Regulation Of Histone Acetylation
- Positive Regulation Of Histone H3-K4 Methylation
- Positive Regulation Of Histone H3-K9 Acetylation
- Positive Regulation Of Histone H3-K9 Methylation
- Positive Regulation Of Histone H4-K16 Acetylation
- Positive Regulation Of Histone H4-K20 Methylation
- Positive Regulation Of Protein Ubiquitination
- Positive Regulation Of Transcription, Dna-Templated
- Positive Regulation Of Transcription From Rna Polymerase Ii Promoter
- Positive Regulation Of Vascular Endothelial Growth Factor Production
- Postreplication Repair
- Protein Autoubiquitination
- Protein K6-Linked Ubiquitination
- Protein Sumoylation
- Protein Ubiquitination
- Regulation Of Apoptotic Process
- Regulation Of Cell Proliferation
- Regulation Of Dna Methylation
- Regulation Of Gene Expression By Genetic Imprinting
- Regulation Of Signal Transduction By P53 Class Mediator
- Regulation Of Transcription From Rna Polymerase Iii Promoter
- Regulation Of Transcription From Rna Polymerase Ii Promoter
- Response To Estrogen
- Response To Ionizing Radiation
- Strand Displacement
- Transcription, Dna-Templated
- Brain Development
- Positive Regulation Of Protein Import Into Nucleus, Translocation
- Response To Estradiol
- Response To Nutrient